Emergent BioSolutions Inc
NYSE:EBS

Watchlist Manager
Emergent BioSolutions Inc Logo
Emergent BioSolutions Inc
NYSE:EBS
Watchlist
Price: 12.51 USD 1.21% Market Closed
Market Cap: 657m USD

Emergent BioSolutions Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Emergent BioSolutions Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Emergent BioSolutions Inc
NYSE:EBS
Cash from Operating Activities
$13m
CAGR 3-Years
-60%
CAGR 5-Years
-50%
CAGR 10-Years
-18%
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

Emergent BioSolutions Inc
Glance View

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,416 full-time employees. The company went IPO on 2006-11-15. The firm is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. The company provides solutions for public health threats through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. The firm also offers a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers.

EBS Intrinsic Value
22.97 USD
Undervaluation 46%
Intrinsic Value
Price

See Also

What is Emergent BioSolutions Inc's Cash from Operating Activities?
Cash from Operating Activities
13m USD

Based on the financial report for Sep 30, 2025, Emergent BioSolutions Inc's Cash from Operating Activities amounts to 13m USD.

What is Emergent BioSolutions Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-18%

Over the last year, the Cash from Operating Activities growth was -92%. The average annual Cash from Operating Activities growth rates for Emergent BioSolutions Inc have been -60% over the past three years , -50% over the past five years , and -18% over the past ten years .

Back to Top